Low-Dose Remifentanil in Preterm Cesarean Section with General Anesthesia: A Randomized Controlled Trial

Area of Science:

• Anesthesiology
• Obstetrics
• Neonatology

Background:

• Current Cesarean section general anesthesia protocols administer opioids post-cord clamping.
• Investigating remifentanil's effect before cord clamping may optimize maternal and neonatal outcomes.
• Preterm neonates require careful consideration during maternal anesthesia for Cesarean delivery.

Purpose of the Study:

• To test if pre-cord clamping remifentanil reduces maternal supplemental anesthetic needs.
• To evaluate the impact of pre-cord clamping remifentanil on maternal hemodynamics.
• To assess neonatal adaptation in preterm infants following maternal remifentanil administration before cord clamping.

Main Methods:

• A Phase III, double-blind, randomized, placebo-controlled trial.
• Parturients undergoing Cesarean section under general anesthesia before 37 weeks gestation were enrolled.
• Primary outcome: Apgar scores <7 at 5 minutes; secondary outcomes included maternal hemodynamics and neonatal respiratory status.

Main Results:

• No significant difference in Apgar scores at 5 minutes between remifentanil and placebo groups (33.3% vs 44.0%, p=0.45).
• Maternal hemodynamic parameters, anesthesia duration, and cumulative drug dose did not differ between groups.
• No differences observed in cord gases, or neurodevelopmental/feeding scores at 1-2 years corrected age.

Conclusions:

• Low-dose remifentanil before cord clamping in Cesarean sections is safe for mothers and preterm neonates.
• The study did not find improved maternal or neonatal outcomes with pre-cord clamping remifentanil.
• Further research may explore alternative strategies for optimizing anesthesia in this population.